Rubella Vaccine

Subscribe to Selected New Research on Rubella Vaccine

363 relevant articles (9 outcomes, 22 trials/studies) found for this Bio-Agent

Description: A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)

Also Known As:

Vaccine, Rubella

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 314

Measles-Mumps-Rubella Vaccine: 539

Rudivax: 6

Experts

1.	Bermal, Nancy: 2 articles (03/2004 - 09/2003)
2.	Leboulleux, Didier: 2 articles (03/2004 - 09/2003)
3.	Desauziers, Eric: 2 articles (03/2004 - 09/2003)
4.	Gatchalian, Salvacion: 2 articles (03/2004 - 09/2003)
5.	Ramsay, M: 2 articles (12/2003 - 01/2001)
6.	Petrovic, M: 2 articles (12/2003 - 01/2001)
7.	DeStefano, F: 2 articles (08/2001 - 01/2000)
8.	Chen, R T: 2 articles (08/2001 - 01/2000)
9.	Donnelly, P D: 2 articles (06/2000 - 03/2000)
10.	Mason, B W: 2 articles (06/2000 - 03/2000)

Related Diseases

1.	Measles 05/21/2009 - "Then, a new vaccination program, vaccinating twice by using the combined measles and rubella vaccine, was started in 2006. " 12/01/2007 - "In December 2003, a nationwide immunization campaign was conducted targeting 33,579,082 people between the ages of 5 and 25 years with a combined measles and rubella vaccine; 98% of the target population was vaccinated. " 11/01/2005 - "OBJECTIVE: To evaluate the seroprevalence, seroconversion, anamnesic response and events temporally associated with immune status pre and post immunization with measles and rubella vaccine in health personnel from a public University in Guadalajara, Mexico. " 05/15/2003 - "This catch-up campaign took place in November 2000: 867,000 doses of measles-rubella vaccine were administered for an estimated coverage of 99%. " 01/01/2002 - "We investigated the antibody responses and clinical adverse reactions after immunization with live combined measles and rubella vaccine (HF vaccine) in 442 healthy children, aged 12-90 months of age. " Order ALL the reference details at left...
2.	Mumps 09/01/2001 - "National and local pilot programmes did not succeed to promote vaccination in countees with a low measle-mumps-rubella vaccine coverage. " 03/01/1999 - "In both groups, more than 90% of infants showed an immune response to the mumps and rubella vaccine strains at 14 months of age. " 06/01/1973 - "Occurrence following combined mumps-rubella vaccine." 07/01/1997 - "Eighty-three percent of those who thought the efficacy of measles, mumps, and rubella vaccine would not be affected by a URI recommended vaccination vs only 8% of physicians who thought efficacy would decrease (P < .001). " 06/01/1988 - "These results suggest that this combined vaccine would be effective and safe in a British population and give further support for the introduction of the combined measles, mumps, and rubella vaccine to Britain." Order ALL the reference details at left...
3.	Rubella (German Measles) 07/01/1983 - "These results indicate that rubella vaccine is highly effective in preventing clinical rubella and do not support proposals for routine revaccination." 11/16/2009 - "This study provides confirmatory evidence for an association between specific class I and II HLA markers and haplotypes with rubella vaccine-induced humoral responses and lends further weight to their influence on rubella immune responses." 06/01/1997 - "In order to develop a valid immunization schedule on the initial vaccination at different age of domestic BRD II strain rubella vaccine, a total number of 268 children at the age of 6 to 18 months from Yantai city of Shandong Province, China were selected for the serological study on hemagglutination inhibition (HI) antibody level against rubella from August to October, 1995. " 11/01/1989 - "The present study documents the relationship between the development of rubella vaccine-associated arthropathy and isotype-specific rubella antibody responses in a prospectively studied population of 44 adult rubella hemagglutination inhibition (HAI) seronegative females undergoing rubella immunization. " 07/29/1978 - "Rubella vaccination in Australia: 2. Experience with the RA27/3 rubella vaccine and results of a double-blind trial in schoolgirls." Order ALL the reference details at left...
4.	Congenital Rubella Syndrome (Syndrome, Congenital Rubella) 03/01/2009 - "OBJECTIVE: To examine weather exposure to rubella vaccine during 1-4 wk periconceptional period can cause congenital rubella syndrome (CRS). " 11/01/2006 - "Also, rubella vaccine induced favorable immunity in a part of the childbearing age female (15-25 years) population, which could prevent congenital rubella syndrome among those females." 06/01/2006 - "An effective live attenuated rubella vaccine was available since 1969 and congenital rubella syndrome can be prevented with appropriate vaccination. " 01/08/2005 - "BACKGROUND: WHO recommends that countries considering introduction of rubella vaccine into their immunisation programme assess their burden of congenital rubella syndrome, to determine whether vaccination is warranted. " 01/01/2005 - "In 1969, the first rubella vaccine was licensed for use, and the Centers for Disease Control and Prevention (CDC) began its National Congenital Rubella Syndrome Registry. " Order ALL the reference details at left...
5.	Chickenpox 05/02/2008 - "Also, these syndromes have not been reported to varicella or rubella vaccine pregnancy registries. " 10/01/1986 - "This assumes that vaccine would be administered only once with measles, mumps, and rubella vaccine, that there would be no increase in the number of varicella cases in older persons who are at increased risk for complications, and that there would be no deleterious effect on the occurrence and severity of herpes zoster.(ABSTRACT TRUNCATED AT 250 WORDS)" 06/01/2002 - "Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children." 11/01/2008 - "RESULTS: The review identified 6 case series and 2 case reports describing 114 solid organ transplant recipients and one case series describing 27 bone marrow transplant recipients who had received a combined total of 206 doses of live varicella, measles, mumps, or rubella vaccine while on immunosuppression. " 01/01/2008 - "There were no clinically relevant changes in the immunogenicity of DTaP-IPV/Hib when coadministered with pneumococcal-7-valent-CRM197 vaccine or measles, mumps, and rubella vaccine and varicella zoster vaccine at 15 months. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Chickenpox Vaccine (Vaccine, Varicella)
2.	Measles Vaccine
3.	Immunoglobulins (Immunoglobulin)
4.	6-Mercaptopurine (Mercaptopurine)
5.	Methotrexate (Mexate)
6.	Ibuprofen (Motrin)
7.	Vaccines
8.	Antibodies
9.	Hepatitis B Vaccines (Hepatitis B Vaccine)
10.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Transplants (Transplant)
4.	Subcutaneous Injections
5.	Electrodes (Electrode)

Best Treatments:
Research Summary Report
on Measles

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 208 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>